Generation of retroviral packaging and producer cell lines for large-scale vector production and clinical application: improved safety and high titer.
about
Retroviral Vector Biosafety: Lessons from SheepThe use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene deliveryDNA as therapeutics; an update.Blockade of type I interferon (IFN) production by retroviral replicating vectors and reduced tumor cell responses to IFN likely contribute to tumor selectivityA microfluidic bioreactor for increased active retrovirus output.Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media.Retrovirus-mediated tk gene therapy of implanted human breast cancer in nude mice under the regulation of Tet-On.Direct evidence for the absence of intercellular trafficking of VP22 fused to GFP or to the herpes simplex virus thymidine kinase.Construction of a retroviral vector production system with the minimum possibility of a homologous recombination.Optimization of retroviral vector generation for clinical application.Cell culture processes for the production of viral vectors for gene therapy purposes.Transduction rate constant as more reliable index quantifying efficiency of retroviral gene delivery.Apical barriers to airway epithelial cell gene transfer with amphotropic retroviral vectors.Suspension packaging cell lines for the simplified generation of T-cell receptor encoding retrovirus vector particles.Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in cell factories.
P2860
Q24792892-BD303087-8065-44A9-8898-3324B4D90FFBQ24804110-EB8F695D-4EF7-44AA-8476-5CFF6A2C99BEQ33836499-783066DC-36F7-444D-B545-CCAA0C144703Q34059493-4BA6E259-D9C8-41A1-9D8B-2C4242C08039Q40032818-3A0713BB-C6D2-48AD-8249-04A4C02303A7Q40069386-62AE12D7-D120-44D6-B3C5-AF301CCD989DQ40383542-E7A26A86-BA1B-4A30-A593-96BB12BD0112Q40504496-B17EF101-EECC-4262-B931-94ADA494E6A1Q40655740-2E8705FB-B15A-4B4A-8AAA-225954FA347AQ40774723-D0CF2D46-CF16-4192-8443-5F2DFDEF3A62Q41856876-98A9F151-2D53-410B-96BD-C2EBBACDA078Q42819426-110D8767-8A4B-4843-93B4-B1D2289DD7BDQ44042210-C0A995C9-0A63-4A9C-A3FA-69194D8EB506Q45865231-8650FCE6-76EB-4215-A984-FAA114812E56Q45887098-27749916-8688-40C6-B64D-AA52196ABFC9
P2860
Generation of retroviral packaging and producer cell lines for large-scale vector production and clinical application: improved safety and high titer.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Generation of retroviral packa ...... mproved safety and high titer.
@en
type
label
Generation of retroviral packa ...... mproved safety and high titer.
@en
prefLabel
Generation of retroviral packa ...... mproved safety and high titer.
@en
P2093
P356
P1433
P1476
Generation of retroviral packa ...... mproved safety and high titer.
@en
P2093
Dubensky TW Jr
Greengard JS
McCormack JE
P304
P356
10.1006/MTHE.2000.0123
P577
2000-09-01T00:00:00Z